 Shares of AtriCure NASDAQ:ATRC were flat in after-market trading after the company reported Q2 results.Quarterly Results Earnings per share fell 123.53 over the past year to 0.38, which beat the estimate of 0.61.Revenue of 40,824,000 decreased by 30.70 from the same period last year, which beat the estimate of 35,450,000.Looking Ahead AtriCure hasnt issued any earnings guidance for the time being.AtriCure hasnt issued any revenue guidance for the time being.How To Listen To The Conference Call Date: Jul 28, 2020View more earnings on ATRCTime: 04:30 PMET Webcast URL: 52-week high: 51.76Companys 52-week low was at 22.57Price action over last quarter: Up 3.59Company Overview AtriCure Inc an atrial fibrillation solutions company that provides products, professional education, and support for clinical science to reduce the economic and social burden of atrial fibrillation. Its products line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offer a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.See more from Benzinga Earnings Scheduled For July 28, 2020C 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 